Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
Sponsor: British Columbia Cancer Agency
This PHASE2 trial investigates Metastatic Castration-Resistant Prostatic Cancer and is currently ongoing. British Columbia Cancer Agency leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 3 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Mar 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- British Columbia Cancer Agency
- Ozmosis Research Inc.
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Box Hill, Australia , Calgary, Canada , Clayton, Australia , Edmonton, Canada , Halifax, Canada , Hamilton, Canada , Kelowna, Canada , Melbourne, Australia , Montreal, Canada , Oshawa, Canada and 5 more locations